General Administration for Pharmaceutical Vigilance





جمهورية مصر العربية هيئة الدواء المصرية الإدارة المركزية للرعاية الصيدلية الادارة العامة لليقظة الصيدلية

# **Direct Healthcare Professional Communication**

#### **Dec 2023**

Linezolid, Averozolid Solution for IV infusion, clarification of yellow color appearance and its intensifying to yellowish brown by time in the solution

Dear Healthcare Professional,

Averroes pharma for pharmaceutical industries in agreement with The General Administration for Pharmaceutical Vigilance of the Central Administration for Pharmaceutical Care at The Egyptian Drug Authority would like to inform you of the following clarification of yellow color appearance and its intensifying to yellowish brown by time in the solution:

## Summary:

• Averroes Pharma clarify to you that you can use the bottle safely when the yellow color appears or its intensifying to yellowish brown color, and there is no risk from it.

## Background:

According to updated data from Averroes pharma's variation study with EDA, we clarify that the color of our product **Averozolid** (Linezolid) solution for IV infusion (each 1 ml contains 2mg of linezolid) is Clear colorless transparent to pale yellow solution (the yellow color can intensify by time to yellowish brown without adversely affecting potency).

So, Averroes Pharma clarify to you that you can use the bottle safely when the yellow color appears or its intensifying to yellowish brown color, and there is no risk from it.

#### Call for reporting

Healthcare professionals are asked to report any suspected adverse reactions via the Egyptian reporting system:

Name: General Administration for Pharmaceutical Vigilance

Email: pv.followup@edaegypt.gov.eg

Online reporting: https://primaryreporting.who-umc.org/EG

QR Code:

Hotline: 15301







Tel.: 237484988 Ext.:1470